See sepsis before it strikes.
AI-driven, gene-expression insight for rapid sepsis risk stratification ~within an hour.
The Problem
Sepsis is a major, under-recognized killer. In 2017 there were an estimated 48.9M cases and 11M sepsis-related deaths worldwide — about 20% of all global deaths. Early recognition is critical. Yet pathogen-based workflows (e.g., blood cultures) often take 2–4 days, delaying precision treatment.
Our approach
Host-response over pathogen detection.
Sepsis.AI analyzes a validated gene-expression signature of immune dysfunction — the body’s early response to infection — rather than waiting for pathogen growth. This supports early risk assessment in ER/ICU settings and helps clinicians act while every hour counts.
How it works
At this time we are recruiting clinical trial partners to validate the test and integrate into your clinical workflow.
Why it matters
Enables earlier intervention, potentially saving lives and reducing severe outcomes.
Helps reduce hospital costs by avoiding delays in diagnosis and unnecessary treatments.
Improves patient outcomes, including long‑term recovery.
Who it’s for
Emergency Departments & ICUs seeking an early, objective risk signal.
Diagnostic labs wanting a gene-expression assay that fits existing workflows.
Health systems & payers prioritizing outcomes, antibiotic stewardship, and throughput.
Clinical researchers studying immune dysregulation in sepsis.
Who We Work With
